GetTopicDetailResponse(id=856b282213, topicName=ASCEND-7, introduction=ASCEND-7, content=null, image=null, comments=1, allHits=1008, url=https://h5.medsci.cn/topic?id=2822, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=95895, tagList=[TagDto(tagId=95895, tagName=ASCEND-7)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1958292, encodeId=7c0f1958292e6, content=<a href='/topic/show?id=856b282213' target=_blank style='color:#2F92EE;'>#ASCEND-7#</a>, objectTitle=吳一龍教授：ASCEND-7研究驚艷ESMO，塞瑞替尼為ALK陽性有癥狀腦轉(zhuǎn)移和腦膜轉(zhuǎn)移NSCLC患者帶來獲益, objectType=article, longId=181755, objectId=c3af181e55db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3af181e55db, replyNumber=0, likeNumber=71, createdTime=2020-06-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3af181e55db, moduleTitle=吳一龍教授：ASCEND-7研究驚艷ESMO，塞瑞替尼為ALK陽性有癥狀腦轉(zhuǎn)移和腦膜轉(zhuǎn)移NSCLC患者帶來獲益, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c3af181e55db)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
